FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Olaf Stüve

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Mouse

Anatomy

Procedures

Clinical Trials as Topic

Concepts & Ideas

Co-author Network

Publications

TOP 3
Paulus S Rommer; Olaf Stüve
Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.
Martin Stangel; Olaf Stüve; Sten Fredrikson; Edgar Meinl; Axel Petzold; Hayrettin Tumani
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.
Bernd C Kieseier; Verena I Leussink; Anne K Mausberg; Marius Ringelstein; Olaf Stüve; Bernd Turowski; Orhan Aktas; Gerald Antoch; Thomas Dehmel; Norbert Goebels; Hans-Peter Hartung
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Olaf Stüve (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Paulus S Rommer; Olaf Stüve
Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.
Current treatment options in neurology 2013;15(3):241-58.
2013: Martin Stangel; Olaf Stüve; Sten Fredrikson; Edgar Meinl; Axel Petzold; Hayrettin Tumani
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.
Nature reviews. Neurology 2013;9(5):267-76.
2013: Bernd C Kieseier; Verena I Leussink; Anne K Mausberg; Marius Ringelstein; Olaf Stüve; Bernd Turowski; Orhan Aktas; Gerald Antoch; Thomas Dehmel; Norbert Goebels; Hans-Peter Hartung
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses.
JAMA neurology 2013;70(3):390-3.
2013: Doris Lambracht-Washington; Bao-xi Qu; Larry D Anderson; Todd N Eagar; Min Fu; Olaf Stüve; Roger N Rosenberg
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.
Journal of neuroimmunology 2013;254(1-2):63-8.
2013: Silvia Rossi; M Salvetti; V Studer; Olaf Stüve; G Coarelli; G Cutter; Valentina De Chiara; A Fornasiero; Francesco Monteleone; C Motta; F Barbieri; Giorgio Bernardi; Diego Centonze
Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2013;20(1):87-94.
2013: Silvia Rossi; Marco Salvetti; Valeria Studer; Olaf Stüve; Francesca Barbieri; Luca Battistini; Giorgio Bernardi; Fabio Buttari; Gary Cutter; Valentina De Chiara; Francesco Monteleone; Caterina Motta; Diego Centonze
A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(1):59-68.
2012: Olaf Stüve; Bernhard Hemmer
Time to talk about timing--when to start, stop and change anti-migratory drugs in MS.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(11):1514-6.
2012: Ellen Marder; Michael Ragland; Pramod Gupta; Olaf Stüve
Cerebral and cervical venous outflow abnormalities are dynamic.
Archives of neurology 2012;69(10):1380-1.
2012: Benjamine Arellano; Jeffrey L Bennett; Chella David; Thomas G Forsthuber; Benjamin M Greenberg; Rehana Hussain; Doris Lambracht-Washington; Alanna M Ritchie; Lawrence Steinman; Jane Yoon; Tresa Zacharias; Sima Zein; Olaf Stüve
Human aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with neuromyelitis optica.
Archives of neurology 2012;69(9):1125-31.
2012: Thorsten Nolting; Sieghart Sopper; Olaf Stüve; Gabriele Arendt; Hans-Peter Hartung; Ingo-W Husstedt; Eleni Koutsilieri; Antje Lindecke; Matthias Maschke
Cytokine levels in CSF and neuropsychological performance in HIV patients.
Journal of neurovirology 2012;18(3):157-61.
2012: Emmanuelle Waubant; B Weinstock-Guttman; Scott S Zamvil; Amit Bar-Or; Peter A Calabresi; J A Cohen; A Cross; L Ding; A Goodman; D Iklé; N Kachuck; M Kita; H Kopetskie; Michele K Mass; A Miller; Masoud Mokhtarani; S Murphy; Daniel Pelletier; Jana Preiningerova; M Racke; E Rosenberg; S Schwid; C Spencer; Olaf Stüve; Timothy L Vollmer
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.
Neurology 2012;78(15):1171-8.
2012: Roberto Bomprezzi; Darin T Okuda; Olaf Stüve; Yazan J Alderazi; Elliot M Frohman
From injection therapies to natalizumab: views on the treatment of multiple sclerosis.
Therapeutic advances in neurological disorders 2012;5(2):97-104.
2012: Alexandre Prat; Olaf Stüve
Firategrast: natalizumab in a pill?
Lancet neurology 2012;11(2):120-1.
2012: Ann M Stowe; Olaf Stüve; Bradley K Wacker; Petra D Cravens; Angela B Freie; Ruilong Hu; Min K Li; Jennifer L Perfater; Jeffrey M Gidday
CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke.
Journal of neuroinflammation 2012;9():33.
2012: Martin S Weber; Uwe Zettl; Bernhard Hemmer; Helena C Kronsbein; Klaus Lehmann-Horn; Til Menge; Johann Sellner; Olaf Stüve
Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects.
Current pharmaceutical design 2012;18(2):209-19.
2012: Uwe K Zettl; Olaf Stüve; Robert Patejdl
Immune-mediated CNS diseases: a review on nosological classification and clinical features.
Autoimmunity reviews 2012;11(3):167-73.
2011: Bernd C Kieseier; Olaf Stüve
Multiple sclerosis: combination therapy in MS--still a valid strategy.
Nature reviews. Neurology 2011;7(12):659-60.
2011: Bridget A Bagert; Ellen Marder; Olaf Stüve
Chronic cerebrospinal venous insufficiency and multiple sclerosis.
Archives of neurology 2011;68(11):1379-84.
2011: Amer Awad; Olaf Stüve
Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices.
Current neuropharmacology 2011;9(3):417-28.
2011: Doris Lambracht-Washington; Bao-Xi Qu; Larry D Anderson; Todd N Eagar; Min Fu; Olaf Stüve; Roger N Rosenberg
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.
Cellular and molecular neurobiology 2011;31(6):867-74.
2011: Amer M Awad; Ellen Marder; Ron Milo; Olaf Stüve
Multiple sclerosis and chronic cerebrospinal venous insufficiency: a critical review.
Therapeutic advances in neurological disorders 2011;4(4):231-5.
2011: Bernd C Kieseier; Heinz Wiendl; Hans-Peter Hartung; Verena-Isabell Leussink; Olaf Stüve
Risks and benefits of multiple sclerosis therapies: need for continual assessment?
Current opinion in neurology 2011;24(3):238-43.
2011: Johann Sellner; Jörg Kraus; Amer Awad; Ron Milo; Bernhard Hemmer; Olaf Stüve
The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors.
Autoimmunity reviews 2011;10(8):495-502.
2011: Bernd C Kieseier; Olaf Stüve
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
Nature reviews. Neurology 2011;7(5):255-62.
2011: Olaf Stüve; Joanne Wang; Andrew Chan; Bernhard Hemmer; Sabine Cepok; Stefan Nessler; Frauke Zipp; Myla D Goldman; Sven G Meuth; Carsten Korth; Doris Lambracht-Washington
No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis.
Archives of neurology 2011;68(2):264-5.
2011: Amer Awad; Marlyn Mayo; Olaf Stüve; Rafeed Alkawadri; Bachir Estephan
Anti-glutamic Acid decarboxylase antibody-associated ataxia as an extrahepatic autoimmune manifestation of hepatitis C infection: a case report.
Case reports in neurological medicine 2011;2011():975152.
2011: Amer Awad; Bachir Estephan; Olaf Stüve
CNS intravascular lymphoma: a case report.
Case reports in neurological medicine 2011;2011():515182.
2011: Clemens Warnke; Olaf Stüve; Anna Fogdell-Hahn; Hans-Peter Hartung; Bernd C Kieseier
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.
Neuropsychiatric disease and treatment 2011;7():519-27.
2011: Petra D Cravens; Todd N Eagar; Emily Herndon; Rehana Z Hussain; Doris Lambracht-Washington; Stefan Nessler; Ramya Vinnakota; Tresa E Zacharias; Scott S Zamvil; Li-Hong Ben; Olaf Stüve
Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet.
Journal of neuroinflammation 2011;8():73.
2011: Gerd Meyer zu Hörste; Johanna I Müller; Olaf Stüve; Peter Gmeiner; Hans-Peter Hartung; Carsten Korth; Helmar C Lehmann; Stefan Löber; Anne K Mausberg; Bernd C Kieseier
Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules.
PloS one 2011;6(6):e21223.
2011: Nancy L Monson; Petra D Cravens; Rehana Hussain; Christopher T Harp; Matthew Cummings; Maria de Pilar Martin; Li-Hong Ben; Julie Do; Jeri-Anne Lyons; Amy Lovette-Racke; Anne H Cross; Michael K Racke; Olaf Stüve; Mark Shlomchik; Todd N Eagar
Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.
PloS one 2011;6(2):e17103.
2010: Johann Sellner; Martin S Weber; Patrick Vollmar; Heinrich P Mattle; Bernhard Hemmer; Olaf Stüve
The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?
CNS neuroscience & therapeutics 2010;16(6):362-73.
2010: Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; OA Khan; Todd N Eagar
Translational research in neurology and neuroscience 2010: multiple sclerosis.
Archives of neurology 2010;67(11):1307-15.
2010: Amer M Awad; Olaf Stüve
Immunopathogenesis of multiple sclerosis: new insights and therapeutic implications.
Continuum (Minneapolis, Minn.) 2010;16(5 Multiple Sclerosis):166-80.
2010: Maria F Pacheco; Heidi Jacobe; Todd N Eagar; Olaf Stüve
Reversible alopecia associated with glatiramer acetate.
Archives of neurology 2010;67(9):1154.
2010: Clemens Warnke; Til Menge; Hans-Peter Hartung; Michael K Racke; Petra D Cravens; Jeffrey Bennett; Elliot M Frohman; Benjamin M Greenberg; Scott S Zamvil; Ralf Gold; Bernhard Hemmer; Bernd C Kieseier; Olaf Stüve
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
Archives of neurology 2010;67(8):923-30.
2010: Bao-Xi Qu; Doris Lambracht-Washington; Min Fu; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.
Vaccine 2010;28(32):5280-7.
2010: Amer Awad; Olaf Stüve
Multiple sclerosis in the elderly patient.
Drugs & aging 2010;27(4):283-94.
2010: Olaf Stüve; Benjamin M Greenberg
Anticipated benefits and surprising effects of daclizumab in multiple sclerosis.
Lancet neurology 2010;9(4):337-8.
2010: Wei Hu; Stefan Nessler; Bernhard Hemmer; Todd N Eagar; Lawrence P Kane; S Rutger Leliveld; Andreas Müller-Schiffmann; Anne R Gocke; Amy Lovett-Racke; Li-Hong Ben; Rehana Z Hussain; Andreas Breil; Jeffrey L Elliott; Krishna Puttaparthi; Petra D Cravens; Mahendra P Singh; Benjamin Petsch; Lothar Stitz; Michael K Racke; Carsten Korth; Olaf Stüve
Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling.
Brain : a journal of neurology 2010;133(Pt 2):375-88.
2010: Elliot M Frohman; Gary R Cutter; Gina Remington; Hongjiang Gao; Howard Rossman; Bianca Weinstock-Guttman; Jacqueline E Durfee; Amy Conger; Ellen Carl; Katherine Treadaway; Eric Lindzen; Amber Salter; Teresa C Frohman; Anjali Shah; Angela Bates; Jennifer L Cox; Michael G Dwyer; Olaf Stüve; Benjamin M Greenberg; Michael K Racke; Robert Zivadinov
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Therapeutic advances in neurological disorders 2010;3(1):15-28.
2010: Gina M Remington; Katherine Treadaway; Teresa C Frohman; Amber Salter; Olaf Stüve; Michael K Racke; Kathleen Hawker; Federica Agosta; Maria Pia Sormani; Massimo Filippi; Elliot M Frohman
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
Therapeutic advances in neurological disorders 2010;3(1):3-13.
2010: Clemens Warnke; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Drug design, development and therapy 2010;4():117-26.
2009: Rehana Z Hussain; Steven C Hopkins; Elliot M Frohman; Todd N Eagar; Petra C Cravens; Benjamin M Greenberg; Steven Vernino; Olaf Stüve
Direct and consensual murine pupillary reflex metrics: establishing normative values.
Autonomic neuroscience : basic & clinical 2009;151(2):164-7.
2009: Olaf Stüve
Knowns and unknowns in the future of multiple sclerosis treatment.
Journal of the neurological sciences 2009;287 Suppl 1():S30-6.
2009: Amer M Awad; Bachir Estephan; Worthy Warnack; Olaf Stüve
Optic neuritis presenting with amaurosis fugax.
Journal of neurology 2009;256(12):2100-3.
2009: Amer Awad; Olaf Stüve
Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.
Therapeutic advances in neurological disorders 2009;2(6):50-61.
2009: Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.
JAMA : the journal of the American Medical Association 2009;302(16):1796-802.
2009: Olaf Stüve; Heinz Wiendl
Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?
Neurology 2009;73(17):1346-7.
2009: Olaf Stüve; Richard M Ransohoff
Immunotherapy for multiple sclerosis: the curious case of interferon beta.
Archives of neurology 2009;66(10):1193-4.
2009: Bernd C Kieseier; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve
The future of multiple sclerosis therapy.
Pharmacological research : the official journal of the Italian Pharmacological Society 2009;60(4):207-11.
2009: Thorsten Nolting; Antje Lindecke; Eleni Koutsilieri; Matthias Maschke; Ingo-W Husstedt; Sieghart Sopper; Olaf Stüve; Hans-Peter Hartung; Gabriele Arendt
Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency virus-positive patients at distinct stages of infection by solid-phase protein array.
Journal of neurovirology 2009;15(5-6):390-400.
2009: Andreas Schweikert; Marcus Kremer; Florian Ringel; Thomas Liebig; Justus Duyster; Olaf Stüve; Bernhard Hemmer; Achim Berthele
Primary central nervous system lymphoma in a patient treated with natalizumab.
Annals of neurology 2009;66(3):403-6.
2009: Maria del Pilar Martin; Petra D Cravens; Ryan Winger; Bernd C Kieseier; Sabine Cepok; Todd N Eagar; Scott S Zamvil; Martin S Weber; Elliot M Frohman; Betty K Kleinschmidt-Demasters; Thomas J Montine; Bernhard Hemmer; Christina M Marra; Olaf Stüve
Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Archives of neurology 2009;66(8):1016-20.
2009: Frauke Otto; Eva Neuen-Jacob; Gabriele Arendt; Olaf Stüve; Hans-Peter Hartung
A 69-year-old man with left hemispheric necrotizing mass lesion.
Brain pathology (Zurich, Switzerland) 2009;19(3):541-4.
2009: Jeffrey L Bennett; Olaf Stüve
Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications.
Clinical neuropharmacology 2009;32(3):121-32.
2009: Harald H Hofstetter; Olaf Stüve; Hans-Peter Hartung
Is 1+1 0, 1, 2, or 11? Arithmetics of antiinflammatory agents in autoimmunity.
Experimental neurology 2009;217(1):4-6.
2009: Katherine Treadaway; Gary R Cutter; Amber Salter; Sharon Lynch; James Simsarian; John Corboy; Douglas Jeffery; Bruce Cohen; Ken Mankowski; Joseph Guarnaccia; Lawrence Schaeffer; Roy Kanter; David Brandes; Charles Kaufman; David Duncan; Ellen Marder; Arthur Allen; John Harney; Joanna Cooper; Douglas Woo; Olaf Stüve; Michael Racke; Elliot M Frohman
Factors that influence adherence with disease-modifying therapy in MS.
Journal of neurology 2009;256(4):568-76.
2009: Roger Rosenberg; Olaf Stüve; Todd Eagar
200 years after Darwin.
JAMA : the journal of the American Medical Association 2009;301(6):660-2.
2009: Olaf Stüve; Petra D Cravens; Elliot M Frohman; J Theodore Phillips; G M Remington; G von Geldern; Sabine Cepok; M P Singh; J W Cohen Tervaert; M De Baets; D MacManus; D H Miller; E W Radü; Elizabeth Cameron; Nancy L Monson; S Zhang; R Kim; Bernhard Hemmer; Michael K Racke
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
Neurology 2009;72(5):396-401.
2009: Olaf Stüve; Carsten Korth; Pablo Gabatto; Elizabeth Cameron; Wei Hu; Todd N Eagar; Nancy L Monson; Elliot M Frohman; Michael K Racke; Cyrus Zabetian; Jorge R Oksenberg
Genetic polymorphism at codon 129 of the prion protein gene is not associated with multiple sclerosis.
Archives of neurology 2009;66(2):280-1.
2009: Olaf Stüve; Verena I Leussink; Ruth Fröhlich; Bernhard Hemmer; Hans-Peter Hartung; Til Menge; Bernd C Kieseier
Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
Archives of neurology 2009;66(2):259-61.
2009: Nancy D Richert; Eduard Kraft; Olaf Stüve
Visualizing the cause of gray matter atrophy in multiple sclerosis.
Archives of neurology 2009;66(2):159-60.
2009: Roger Rosenberg; Olaf Stüve; Todd Eagar
200 years after Darwin.
Archives of neurology 2009;66(2):153-5.
2009: Mahendra P Singh; Gerd Meyer zu Hörste; Wei Hu; Anne K Mausberg; Petra D Cravens; Todd Eagar; Stefan Löber; Ralf Klingenstein; Peter Gmeiner; Carsten Korth; Bernd C Kieseier; Olaf Stüve
Quinpramine is a novel compound effective in ameliorating brain autoimmune disease.
Experimental neurology 2009;215(2):397-400.
2009: Clemens Warnke; Gerd Meyer zu Hörste; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Review of teriflunomide and its potential in the treatment of multiple sclerosis.
Neuropsychiatric disease and treatment 2009;5():333-40.
2009: Wei Hu; Josbert Metselaar; Li-Hong Ben; Petra D Cravens; Mahendra P Singh; Elliot M Frohman; Todd N Eagar; Michael K Racke; Bernd C Kieseier; Olaf Stüve
PEG minocycline-liposomes ameliorate CNS autoimmune disease.
PloS one 2009;4(1):e4151.
2008: Olaf Stüve; Ralf Gold; Andrew Chan; Eilhard Mix; Uwe Zettl; Bernd C Kieseier
alpha4-Integrin antagonism with natalizumab: effects and adverse effects.
Journal of neurology 2008;255 Suppl 6():58-65.
2008: Andrew Chan; Olaf Stüve; Nicolas von Ahsen
Immunosuppression in clinical practice: approaches to individualized therapy.
Journal of neurology 2008;255 Suppl 6():22-7.
2008: Bernd C Kieseier; Heinz Wiendl; Verena I Leussink; Olaf Stüve
Immunomodulatory treatment strategies in multiple sclerosis.
Journal of neurology 2008;255 Suppl 6():15-21.
2008: Maria del Pilar Martin; Petra D Cravens; Ryan Winger; Elliot M Frohman; Michael K Racke; Todd N Eagar; Scott S Zamvil; Martin S Weber; Bernhard Hemmer; Nitin J Karandikar; B K Kleinschmidt-DeMasters; Olaf Stüve
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
Archives of neurology 2008;65(12):1596-603.
2008: Olaf Stüve
The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
Journal of the neurological sciences 2008;274(1-2):39-41.
2008: Michael K Racke; Olaf Stüve
Natalizumab: Increased Vigilance is Required in Treating Patients with Multiple Sclerosis.
Therapeutic advances in neurological disorders 2008;1(3):155-6.
2008: Harald H Hofstetter; Olaf Stüve; Hans-Peter Hartung
Fine-tuning the homeostasis of regulatory T cells: new mechanism of immunomodulatory therapy in multiple sclerosis.
Archives of neurology 2008;65(11):1417-8.
2008: Olaf Stüve; Todd N Eagar
B cells, antibodies, and tertiary lymphoid tissue in MS brains.
Lancet neurology 2008;7(9):766-7.
2008: Verena I Leussink; Helmar C Lehmann; Gerd Meyer zu Hörste; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity.
Journal of neurology 2008;255(9):1436-8.
2008: Harald H Hofstetter; Olaf Stüve; Hans-Peter Hartung
Temporary leukocyte effects in temporal lobe epilepsy?
Experimental neurology 2008;212(2):239-41.
2008: Olaf Stüve; Petra D Cravens; Todd N Eagar
DNA-based vaccines: the future of multiple sclerosis therapy?
Expert review of neurotherapeutics 2008;8(3):351-60.
2008: Wei Hu; Bernd C Kieseier; Elliot M Frohman; Todd N Eagar; Roger Rosenberg; Hans-Peter Hartung; Olaf Stüve
Prion proteins: physiological functions and role in neurological disorders.
Journal of the neurological sciences 2008;264(1-2):1-8.
2008: Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; OA Khan; Hans-Peter Hartung; Olaf Stüve
Disease-modifying agents for multiple sclerosis: recent advances and future prospects.
Drugs 2008;68(17):2445-68.
2008: Elliot M Frohman; Fiona Costello; Olaf Stüve; Peter A Calabresi; David H Miller; Simon J Hickman; Robert Sergott; Amy Conger; Amber Salter; Kimberly H Krumwiede; Teresa C Frohman; Laura J Balcer; Robert Zivadinov
Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis.
Archives of neurology 2008;65(1):26-35.
2008: Olaf Stüve; Jeffrey Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Pharmacological treatment of early multiple sclerosis.
Drugs 2008;68(1):73-83.
2007: Christoph Kleinschnitz; Sven G Meuth; Olaf Stüve; Bernd C Kieseier; Heinz Wiendl
Multiple sclerosis therapy: an update on recently finished trials.
Journal of neurology 2007;254(11):1473-90.
2007: Olaf Stüve; Todd N Eagar; Elliot M Frohman; Petra D Cravens
DNA plasmid vaccination for multiple sclerosis.
Archives of neurology 2007;64(10):1385-6.
2007: Anjali Shah; Eric Eggenberger; Robert Zivadinov; Olaf Stüve; Elliot M Frohman
Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2007;4(4):627-32.
2007: Elliot M Frohman; Anjali Shah; Eric Eggenberger; Luanne Metz; Robert Zivadinov; Olaf Stüve
Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2007;4(4):618-26.
2007: Nathaniel F Watson; Douglas Woo; Michael J Doherty; Elliot M Frohman; Michael K Racke; Marc H De Baets; Hans-Peter Hartung; Bernd C Kieseier; Olaf Stüve
Humoral immune responses after rabies infection.
Archives of neurology 2007;64(9):1355-6.
2007: Martin S Weber; Thomas Prod'homme; Sawsan Youssef; Shannon E Dunn; Cynthia D Rundle; Linda Lee; Juan C Patarroyo; Olaf Stüve; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.
Nature medicine 2007;13(8):935-43.
2007: W Hu; Roger Rosenberg; Olaf Stüve
Prion proteins: a biological role beyond prion diseases.
Acta neurologica Scandinavica 2007;116(2):75-82.
2007: Olaf Stüve; Petra D Cravens; Mahendra P Singh; Elliot M Frohman; J Theodore Phillips; Gina Remington; Wei Hu; Bernhard Hemmer; Michael J Olek; Nancy L Monson; Michael K Racke
High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes.
Archives of neurology 2007;64(7):1055-6.
2007: Fiona Costello; Olaf Stüve; Martin S Weber; Scott S Zamvil; Elliot M Frohman
Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
Current opinion in neurology 2007;20(3):281-5.
2007: Til Menge; Bernd C Kieseier; Stefan Nessler; Bernhard Hemmer; Hans-Peter Hartung; Olaf Stüve
Acute disseminated encephalomyelitis: an acute hit against the brain.
Current opinion in neurology 2007;20(3):247-54.
2007: Bernhard Hemmer; Olaf Stüve
Revised criteria for neuromyelitis optica--a new diagnostic standard?
Nature clinical practice. Neurology 2007;3(3):132-3.
2007: Olaf Stüve; Christina M Marra; Petra D Cravens; Mahendra P Singh; Wei Hu; Amy E Lovett-Racke; Nancy L Monson; J Theodore Phillips; Jan W Cohen Tervaert; Richard A Nash; Hans-Peter Hartung; Bernd C Kieseier; Michael M Racke; Elliot M Frohman; Bernhard Hemmer
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
Archives of neurology 2007;64(2):169-76.
2007: Olaf Stüve; Jeffrey Bennett
Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases.
CNS drug reviews 2007;13(1):79-95.
2006: Tea Kopadze; Thomas Dehmel; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.
Archives of neurology 2006;63(11):1572-8.
2006: Olaf Stüve; Christina M Marra; Amit Bar-Or; Masaaki Niino; Petra D Cravens; Sabine Cepok; Elliot M Frohman; J Theodore Phillips; Gabriele Arendt; Keith R Jerome; Linda Cook; Francois Grand'Maison; Bernhard Hemmer; Nancy L Monson; Michael K Racke
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Archives of neurology 2006;63(10):1383-7.
2006: Helmar C Lehmann; Hans-Peter Hartung; Gerd R Hetzel; Olaf Stüve; Bernd C Kieseier
Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders.
Archives of neurology 2006;63(8):1066-71.
2006: Helmar C Lehmann; Hans-Peter Hartung; Gerd R Hetzel; Olaf Stüve; Bernd C Kieseier
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders.
Archives of neurology 2006;63(7):930-5.
2006: Olaf Stüve
Statins and the blood-brain barrier: plugging the holes.
Annals of neurology 2006;60(1):1-2.
2006: Bernhard Hemmer; Eiliot Frohman; Hans Peter Hartung; Olaf Stüve
Central nervous system infections - a potential complication of systemic immunotherapy.
Current opinion in neurology 2006;19(3):271-6.
2006: Olaf Stüve; Christina M Marra; Keith R Jerome; Linda Cook; Petra D Cravens; Sabine Cepok; Elliot M Frohman; J Theodore Phillips; Gabriele Arendt; Bernhard Hemmer; Nancy L Monson; Michael K Racke
Immune surveillance in multiple sclerosis patients treated with natalizumab.
Annals of neurology 2006;59(5):743-7.
2006: Stephanie Grubenbecher; Olaf Stüve; Harald Hefter; Carsten Korth
Prion protein gene codon 129 modulates clinical course of neurological Wilson disease.
Neuroreport 2006;17(5):549-52.
2006: Olaf Stüve; Sawsan Youssef; Martin S Weber; Stefan Nessler; Hans-Christian von Büdingen; Bernhard Hemmer; Thomas Prod'homme; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.
The Journal of clinical investigation 2006;116(4):1037-44.
2005: Amy E Lovett-Racke; Petra D Cravens; Anne R Gocke; Michael K Racke; Olaf Stüve
Therapeutic potential of small interfering RNA for central nervous system diseases.
Archives of neurology 2005;62(12):1810-3.
2005: Til Menge; Bernhard Hemmer; Stefan Nessler; Heinz Wiendl; Oliver Neuhaus; Hans-Peter Hartung; Bernd C Kieseier; Olaf Stüve
Acute disseminated encephalomyelitis: an update.
Archives of neurology 2005;62(11):1673-80.
2005: Oliver Neuhaus; Heinz Wiendl; Bernd C Kieseier; Juan J Archelos; Bernhard Hemmer; Olaf Stüve; Hans-Peter Hartung
Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
Journal of neuroimmunology 2005;168(1-2):128-37.
2005: Olaf Stüve; Sabine Cepok; Birte Elias; Andreas Saleh; Hans-Peter Hartung; Bernhard Hemmer; Bernd C Kieseier
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Archives of neurology 2005;62(10):1620-3.
2005: Elliot M Frohman; Olaf Stüve; Eva Havrdova; John R Corboy; Anat Achiron; Robert Zivadinov; Per Soelberg Sorensen; J Theodore Phillips; Brian Weinshenker; Kathleen Hawker; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil; Bruce A C Cree; Stephen Hauser; Howard L Weiner; Michael K Racke; Massimo Filippi
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
Archives of neurology 2005;62(10):1519-30.
2005: Bernhard Hemmer; Olaf Stüve; Bernd C Kieseier; Huub Schellekens; Hans-Peter Hartung
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.
Lancet neurology 2005;4(7):403-12.
2005: Oliver Neuhaus; Olaf Stüve; Juan J Archelos; Hans-Peter Hartung
Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
Journal of the neurological sciences 2005;233(1-2):173-7.
2005: Olaf Stüve; Stefan Nessler; Hans-Peter Hartung; Bernhard Hemmer; Heinz Wiendl; Bernd C Kieseier
[Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis].
Der Nervenarzt 2005;76(6):701-7.
2005: Til Menge; Hans-Peter Hartung; Olaf Stüve
Statins--a cure-all for the brain?
Nature reviews. Neuroscience 2005;6(4):325-31.
2005: Til Menge; Hans-Christian von Büdingen; Scott S Zamvil; Hans-Peter Hartung; Bernd C Kieseier; Olaf Stüve
[Statins for treatment of CNS diseases. Status report from research and clinical practice].
Der Nervenarzt 2005;76(4):426-37.
2005: Oliver Neuhaus; Olaf Stüve; Scott S Zamvil; Hans-Peter Hartung
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
CNS drugs 2005;19(10):833-41.
2004: Olaf Stüve; Michael Racke; Bernhard Hemmer
Viral pathogens in multiple sclerosis: an intriguing (hi)story.
Archives of neurology 2004;61(10):1500-2.
2004: Olaf Stüve; Mariko Kita; Daniel Pelletier; Robert J Fox; Jerome Stone; Donald Goodkin; Scott S Zamvil
Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10 Suppl 1():S58-61.
2004: Oliver Neuhaus; Olaf Stüve; Scott S Zamvil; Hans-Peter Hartung
Are statins a treatment option for multiple sclerosis?
Lancet neurology 2004;3(6):369-71.
2004: Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Statins as potential therapeutic agents in multiple sclerosis.
Current neurology and neuroscience reports 2004;4(3):237-44.
2003: Olaf Stüve; Sawsan Youssef; Shannon Dunn; Anthony J Slavin; Lawrence Steinman; Scott S Zamvil
The potential therapeutic role of statins in central nervous system autoimmune disorders.
Cellular and molecular life sciences : CMLS 2003;60(11):2483-91.
2003: Olaf Stüve; Thomas Prod'homme; Anthony J Slavin; Sawsan Youssef; Shannon Dunn; Lawrence Steinman; Scott S Zamvil
Statins and their potential targets in multiple sclerosis therapy.
Expert opinion on therapeutic targets 2003;7(5):613-22.
2003: Olaf Stüve; Sawsan Youssef; Lawrence Steinman; Scott S Zamvil
Statins as potential therapeutic agents in neuroinflammatory disorders.
Current opinion in neurology 2003;16(3):393-401.
2002: Olaf Stüve; Sawsan Youssef; Anthony J Slavin; Chelsea L King; Juan C Patarroyo; David L Hirschberg; W June Brickey; Jeanne M Soos; Janet F Piskurich; Harold A Chapman; Scott S Zamvil
The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(12):6720-32.
2002: Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Nature 2002;420(6911):78-84.
2002: Olaf Stüve; Bruce C Cree; Hans-Christian von Büdingen; Sawsan Yousef; James D Bowen; Claude P Genain; Stephen L Hauser; Lawrence Steinman; Scott S Zamvil
Approved and future pharmacotherapy for multiple sclerosis.
The neurologist 2002;8(5):290-301.
2002: Jeanne M Soos; Olaf Stüve; Sawsan Youssef; Manuel Bravo; Howard M Johnson; Howard L Weiner; Scott S Zamvil
Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(5):2231-5.
2001: Jeanne M Soos; Jeffrey I Krieger; Olaf Stüve; C L King; Juan C Patarroyo; Kenneth Aldape; Karolina Wosik; Anthony J Slavin; P A Nelson; Jack P Antel; Scott S Zamvil
Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Glia 2001;36(3):391-405.
2001: Olaf Stüve; Carl B Dodrill; Mark D Holmes; John W Miller
The absence of interictal spikes with documented seizures suggests extratemporal epilepsy.
Epilepsia 2001;42(6):778-81.
1999: Olaf Stüve; Scott S Zamvil
Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis.
Current opinion in neurology 1999;12(4):395-401.